Re: Re:
Yes, it would, although I don't know where the big money comes from these days.
.
I don't think Armstrong worried too much about the testing regime, do you? It was both technically and financially surmountable and Verbruggen has taken the exact details to his grave.
For Froome? At a guess I'd say whatever he does that accounts for his dramatic rise is as yet undetectable, or perhaps was a one-off treatment with permanent effects.
He was troubled by the Salbutamol AAF, and the length of time from exposure to outcome coupled with the negative comments from key figures within the UCI and ASO suggested that they are not in his pocket.
Then the case was dropped under rather surprising circumstances, although the scientist responsible for the test expressing a lack of faith in his own test was probably enough to sink the case.
aphronesis said:macbindle said:Yes, we all know that, and no he wasn't talking about winning the Vuelta he was talking about riding the Vuelta. Not sure why you are mentioning it.
You are citing Armstrong's decision to only ride the Tour, and not the other GTs as being a pragmatic, doping related decision. Nothing to do with sharing things out. If you go for 7 straight wins you clearly don't care about being seen to take the pi55.
That is the bit that is in your head. He didn't ride them because it wouldn't have made him any richer, or indeed more famous.
It would now though. Times moved on
Yes, it would, although I don't know where the big money comes from these days.
.
More to the point, aside from pisstaking, I could be mistaken, but seem to recall that fewer targeted races lessened the testing load. Seems that barrier was surmounted.
I don't think Armstrong worried too much about the testing regime, do you? It was both technically and financially surmountable and Verbruggen has taken the exact details to his grave.
For Froome? At a guess I'd say whatever he does that accounts for his dramatic rise is as yet undetectable, or perhaps was a one-off treatment with permanent effects.
He was troubled by the Salbutamol AAF, and the length of time from exposure to outcome coupled with the negative comments from key figures within the UCI and ASO suggested that they are not in his pocket.
Then the case was dropped under rather surprising circumstances, although the scientist responsible for the test expressing a lack of faith in his own test was probably enough to sink the case.